Aspirin for Flushing with Fumarates in MS
Yes, aspirin is supported by FDA drug labeling and clinical evidence to reduce flushing associated with dimethyl fumarate and diroximel fumarate in multiple sclerosis patients. Non-enteric coated aspirin 325 mg taken 30 minutes before fumarate dosing can reduce both the incidence and severity of flushing without affecting gastrointestinal tolerability or drug pharmacokinetics.
FDA-Approved Recommendation
The FDA drug labels for both diroximel fumarate (VUMERITY) and dimethyl fumarate explicitly state that administration of non-enteric coated aspirin (up to 325 mg) 30 minutes prior to dosing may reduce the incidence or severity of flushing 1. This is the highest level of evidence available—direct FDA labeling guidance based on clinical pharmacology studies.
Clinical Evidence Supporting Aspirin Use
Pharmacokinetic and Tolerability Studies
A randomized controlled trial in healthy volunteers (N=56) demonstrated that aspirin pretreatment (325 mg) reduced flushing incidence and intensity without affecting the pharmacokinetic profile of dimethyl fumarate or worsening gastrointestinal events 2. Importantly, aspirin had no effect on the primary pharmacokinetic parameters (AUC or Cmax), confirming no drug-drug interaction that would compromise efficacy.
A larger follow-up study (N=173) over 8 weeks confirmed these findings: aspirin 325 mg given 30 minutes before dimethyl fumarate reduced the incidence, severity, and number of flushing events 3. The flushing events were typically mild-to-moderate, lasted approximately 1 hour, and generally occurred on the first day of treatment. Critically, aspirin had no adverse effect on gastrointestinal events, addressing a common concern about combining these medications.
Mechanism and Clinical Context
The mechanism appears to be prostaglandin-mediated, as elevated plasma concentrations of prostaglandin D2 metabolites were observed in some dimethyl fumarate-treated individuals 2. Aspirin's cyclooxygenase inhibition likely blocks this pathway, explaining its effectiveness.
Practical Implementation Strategy
Dosing protocol:
- Use non-enteric coated aspirin 325 mg (enteric coating delays absorption and reduces effectiveness for this indication)
- Administer 30 minutes before fumarate dosing
- Continue aspirin pretreatment during the initial weeks when flushing is most problematic (typically first month)
Additional flushing management:
- Administer fumarates with food to further reduce flushing incidence 1
- Educate patients that flushing typically improves or resolves over time 4
- Flushing symptoms generally begin soon after initiating treatment and usually improve within the first month
Important Safety Considerations
Gastrointestinal Risk Warning
Critical caveat: The FDA labels include a black box-level warning that serious gastrointestinal reactions (perforation, ulceration, hemorrhage, obstruction) have been reported with fumaric acid esters, including cases with concomitant aspirin use 1. The majority occurred within 6 months of treatment initiation. While aspirin doesn't increase routine GI adverse events in clinical trials, monitor patients closely and discontinue fumarates for new or worsening severe gastrointestinal symptoms.
Contraindications to Aspirin
Do not use aspirin in patients with:
- Aspirin allergy or intolerance
- Active peptic ulcer disease or history of gastrointestinal bleeding
- Concurrent anticoagulation (warfarin, DOACs)
- Concurrent NSAID use
- Bleeding disorders
Alternative Strategies
If aspirin is contraindicated or ineffective:
- Administer with food (primary alternative strategy per FDA labeling)
- Consider temporary dose reduction if flushing is intolerable
- Reassure patients that flushing typically diminishes over 4-8 weeks
- Note that slow dose titration protocols did NOT significantly reduce flushing in controlled trials 3, so this is not a reliable alternative
Clinical Trial Context
In the pivotal dimethyl fumarate trials, 40% of patients experienced flushing, but only 3% discontinued due to flushing 1. Most flushing was mild-to-moderate. This context helps set realistic expectations: aspirin reduces but does not eliminate flushing, and most patients tolerate it even without aspirin.
The evidence strongly supports aspirin use for flushing mitigation, but requires careful patient selection to avoid gastrointestinal complications, particularly in the first 6 months of fumarate therapy.